Alpha 2.0
Login Register
» Authors » Tore K Kvien

Tore K Kvien

Explore the profile of Tore K Kvien including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 409
Citations 19308
Followers 0
Related Specialties
Rheumatology
General Medicine
Pharmacology
Top 10 Co-Authors
Till Uhlig
Desiree van der Heijde
Espen A Haavardsholm
Hilde Berner Hammer
Joseph Sexton
Maxime Dougados
Elisabeth Lie
Josef S Smolen
Karel Pavelka
Siri Lillegraven
Published In
Ann Rheum Dis
Rheumatology (Oxford)
J Rheumatol
RMD Open
Arthritis Rheum
Affiliations
Soon will be listed here.
Recent Articles
1.
Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls
Christensen I, Lillegraven S, Sexton J, Kvien T, Uhlig T, Provan S
Rheumatol Adv Pract . 2025 Mar; 9(1):rkaf017. PMID: 40061449
Objectives: To compare the risk of serious infection across time cohorts in patients with inflammatory arthritis (IA) initiating their first biologic/targeted synthetic DMARD (b/tsDMARD), to that of the general population....
2.
Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study
Li G, Kolan S, Grimolizzi F, Sexton J, Malachin G, Goll G, et al.
Front Med (Lausanne) . 2025 Feb; 12:1526708. PMID: 40012979
Introduction: Achieving remission is a critical therapeutic goal in the management of rheumatoid arthritis (RA). Despite methotrexate being the cornerstone of early RA treatment, a significant proportion of patients fail...
3.
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis
Georgiadis S, Pons M, Rasmussen S, Hetland M, Linde L, Di Giuseppe D, et al.
RMD Open . 2025 Feb; 11(1). PMID: 39979039
Objectives: We aimed to compare various methods for imputing disease activity in longitudinally collected observational data of patients with axial spondyloarthritis (axSpA). Methods: We conducted a simulation study on data...
4.
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, et al.
Ann Rheum Dis . 2024 Dec; PMID: 39739386
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of...
5.
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E, Lauper K, Molina-Collada J, Aletaha D, Askling J, Gente K, et al.
Ann Rheum Dis . 2024 Dec; PMID: 39739385
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice. Objectives: To...
6.
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I, et al.
Lancet Reg Health Eur . 2024 Dec; 48:101121. PMID: 39624496
Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was...
7.
Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey
Ahmadzay Z, Heberg J, Jorgensen J, Ornbjerg L, Ostergaard M, Moller-Bisgaard S, et al.
Rheumatol Adv Pract . 2024 Nov; 8(4):rkae135. PMID: 39611201
Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is...
8.
Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries
Ornbjerg L, Georgiadis S, Kvien T, Michelsen B, Rasmussen S, Pavelka K, et al.
RMD Open . 2024 Nov; 10(4). PMID: 39489531
Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration...
9.
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
Wolf A, Bjorlykke K, Orbo H, Bhandari S, Solum G, Kjonstad I, et al.
EBioMedicine . 2024 Sep; 108:105317. PMID: 39260039
Background: Understanding cellular responses to SARS-CoV-2 immunisations is important for informing vaccine recommendations in patients with inflammatory bowel disease (IBD) and other vulnerable patients on immunosuppressive therapies. This study investigated...
10.
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
Christiansen S, Rasmussen S, Ostergaard M, Pons M, Michelsen B, Pavelka K, et al.
RMD Open . 2024 Jul; 10(3. PMID: 39053949
Objectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods: Prospectively collected data on secukinumab-treated...